Truist lowered the firm’s price target on Varonis (VRNS) to $50 from $70 and keeps a Buy rating on the shares after its Q3 results. The stock fell after weaker than guided Q3 top line results due to deterioration in renewal rates across its On-Prem segment which it has been migrating customers from the past three years, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNS: